Patients with chronic fatigue syndrome and fibromyalgia have higher levels of high-sensitivity C-reactive protein (hsCRP) — a marker of inflammation — compared to healthy individuals, a study has found. The relationship remains true even after adjusting for other variables such as body mass index (BMI), age and smoking status. This finding indicates an inflammatory activity in these patients that may be valuable as a therapy target. The study, “Patients with Fibromyalgia and Chronic Fatigue Syndrome show increased hsCRP compared to healthy controls,” was published in the journal Brain, Behavior and Immunity. Chronic fatigue syndrome (CFS) and fibromyalgia (FM) are distinct chronic disorders that have overlapping clinical characteristics, including pain and fatigue. Interestingly, pain and fatigue are common traits across several different inflammatory disorders. Research also has shown inflammation directly activates pain pathways in the body. As inflammation is a prominent component of the immune system, it has been suggested that the immune system may have a role in the development of CFS and FM. However, the full extent of the connection between CFS, FM and the immune system is not conclusive.